These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1361435)

  • 1. Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities.
    de la Rosette JJ; Karthaus HF; van Kerrebroeck PE; de Boo T; Debruyne FM
    Eur Urol; 1992; 22(3):222-7. PubMed ID: 1361435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study.
    Mehik A; Alas P; Nickel JC; Sarpola A; Helström PJ
    Urology; 2003 Sep; 62(3):425-9. PubMed ID: 12946740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia.
    Martorana G; Giberti C; Di Silverio F; von Heland M; Rigatti P; Colombo R; Casadei G; Pacifico P
    Eur Urol; 1997; 32(1):47-53. PubMed ID: 9266231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome.
    Nickel JC; Krieger JN; McNaughton-Collins M; Anderson RU; Pontari M; Shoskes DA; Litwin MS; Alexander RB; White PC; Berger R; Nadler R; O'Leary M; Liong ML; Zeitlin S; Chuai S; Landis JR; Kusek JW; Nyberg LM; Schaeffer AJ;
    N Engl J Med; 2008 Dec; 359(25):2663-73. PubMed ID: 19092152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group.
    Hansen BJ; Nordling J; Mensink HJ; Walter S; Meyhoff HH
    Scand J Urol Nephrol Suppl; 1994; 157():169-76. PubMed ID: 7524141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Br J Urol; 1993 Nov; 72(5 Pt 1):615-20. PubMed ID: 10071548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group.
    Buzelin JM; Hebert M; Blondin P
    Br J Urol; 1993 Dec; 72(6):922-7. PubMed ID: 7508331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group.
    Schulman CC; De Sy W; Vandendris M; Tomas M; Santoni JP
    Acta Urol Belg; 1994 Dec; 62(4):15-21. PubMed ID: 7540794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Stalla-Bourdillon A; Attali P
    Br J Urol; 1994 Nov; 74(5):579-84. PubMed ID: 7530121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group.
    Teillac P; Delauche-Cavallier MC; Attali P
    Br J Urol; 1992 Jul; 70(1):58-64. PubMed ID: 1379106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alfuzosin (10 mg) does not affect blood pressure in young healthy men.
    Mondaini N; Giubilei G; Ungar A; Gontero P; Cai T; Gavazzi A; Bartoletti R; Geppetti P; Carini M
    Eur Urol; 2006 Dec; 50(6):1292-6; discussion 1297-8. PubMed ID: 16837126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
    van Kerrebroeck P; Jardin A; Laval KU; van Cangh P
    Eur Urol; 2000 Mar; 37(3):306-13. PubMed ID: 10720857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group.
    Jardin A; Bensadoun H; Delauche-Cavallier MC; Attali P
    Lancet; 1991 Jun; 337(8755):1457-61. PubMed ID: 1710750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial.
    Resnick MI; Roehrborn CG
    Prostate Cancer Prostatic Dis; 2007; 10(2):155-9. PubMed ID: 17211442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia.
    Marks LS; Roehrborn CG; Gittelman M; Kim D; Forrest J; Jacobs S
    Urology; 2003 Nov; 62(5):888-93. PubMed ID: 14624914
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bladder-neck opening test in spinal cord injury patients using a new i.v. alpha-blocking agent, alfuzosin.
    Cramer P; Neveux E; Régnier F; Depassio J; Bérard E
    Paraplegia; 1989 Apr; 27(2):119-24. PubMed ID: 2566147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A clinical trial of the treatment of patients with benign prostatic hyperplasia using the alpha 1-adrenoblocker alfuzosin].
    Lopatkin NA; Perepanova TS
    Urol Nefrol (Mosk); 1997; (5):14-6. PubMed ID: 9412005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the new alpha 1-blocker alfuzosin with propranolol as first-line therapy in hypertension.
    Sega R; Marazzi ME; Bombelli M; Vulpis V; Antonacci A; Leto di Priolo S; Pirrelli A; Libretti A
    Pharmacol Res; 1991 Jul; 24(1):41-52. PubMed ID: 1682905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
    Nordling J
    BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of alfuzosin on female primary bladder neck obstruction.
    Athanasopoulos A; Gyftopoulos K; Giannitsas K; Perimenis P
    Int Urogynecol J Pelvic Floor Dysfunct; 2009 Feb; 20(2):217-22. PubMed ID: 18982236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.